Lykon
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2023 |
---|---|---|---|---|---|
Revenues | - | 2.5m | 4.2m | - | 9.3m |
% growth | - | - | 68 % | - | - |
Profit | (1.2m) | (2.0m) | (2.4m) | (3.7m) | - |
% profit margin | - | (79 %) | (57 %) | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
€6.4m | Seed | ||
N/A | Debt | ||
* | €10.0m | Series A | |
* | €2.5m Valuation: €50.0m | Early VC | |
* | N/A | Acquisition | |
Total Funding | CAD28.4m |
Related Content
Recent News about Lykon
EditLykon operates in the personalized health and wellness market, offering at-home blood and DNA tests to help individuals optimize their diet and nutrient intake. The company serves health-conscious consumers looking to tailor their dietary and lifestyle choices based on their unique genetic and metabolic profiles. Lykon's business model revolves around selling test kits directly to consumers through their website, as well as offering subscription-based services for ongoing health monitoring and personalized recommendations. Revenue is generated from the sale of these test kits and subscription services. The company leverages advanced biotechnology to provide actionable insights, making it easier for clients to achieve their health and wellness goals.
Keywords: personalized health, at-home tests, blood analysis, DNA analysis, diet optimization, nutrient balance, genetic profiling, health monitoring, biotechnology, wellness.